BioSpace News Archive

Stay on top of what’s happening at JPM. BioSpace is covering all the key announcements all week.

The drugmaker’s presentation highlights its strong revenue growth, dominant vaccine business and expanding oncology portfolio.

In a presentation led by Robert J. Bradway, Amgen chairman and chief executive officer, the company covered recent acquisitions, Repatha and Lumakras updates, biosimilars and its broader financial outlook.

Tuesday, AbbVie partnered with Anima Biotech to discover and develop mRNA modulators in a collaboration of up to $582 million. The partnership will focus on three oncology and immunology targets.

Pfizer forecasts stable growth in the coming years, driven by a strong product push to cushion its non-COVID business and exclusivity losses.

Complete Genomics showcased its innovative sequencing capacity at the Biotech Showcase 2023, one of the year’s most important investor conferences.

Santhera Pharmaceuticals announces that through a share exchange it will receive the equivalent of CHF 5 million Idorsia shares whichSanthera is free to sell at its own discretion in support of its short-term financial needs.

Valbiotis, a commercially oriented Research and Development company committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces its roadmap for 2023.

Genethon, a unique non-profit gene therapy R&D organization founded by the French Muscular Dystrophy Association, has launched a pivotal clinical trial in Europe for treatment of Crigler-Najjar syndrome, a life threatening liver disease.

Prenetics Global Limited (NASDAQ: PRE) a leader in genomic and diagnostic testing, today announced that ACT Genomics, a company which Prenetics recently acquired a majority stake in, has received clearance from the U.S. Food and Drug Administration (FDA) for ACTOnco, the company’s comprehensive genomic profiling test for solid tumors